Selexipag in Pulmonary Arterial Hypertension: Most Updated Evidence From Recent Preclinical and Clinical Studies.
- Published in:
- Journal of Clinical Pharmacology, 2017, v. 57, n. 5, p. 547, doi. 10.1002/jcph.834
- By:
- Publication type:
- Article
Works matching IS 00912700 AND DT 2017 AND VI 57 AND IP 5
Results: 14
1
2
Evidence for the hERG Liability of Antihistamines, Antipsychotics, and Anti-Infective Agents: A Systematic Literature Review From the ARITMO Project.
- Published in:
- Journal of Clinical Pharmacology, 2017, v. 57, n. 5, p. 558, doi. 10.1002/jcph.838
- By:
- Publication type:
- Article
3
Exposure-Response Analyses Supporting Ticagrelor Dosing Recommendation in Patients With Prior Myocardial Infarction.
- Published in:
- Journal of Clinical Pharmacology, 2017, v. 57, n. 5, p. 573, doi. 10.1002/jcph.839
- By:
- Publication type:
- Article
4
2016 Peer Reviewers, The Journal of Clinical Pharmacology.
- Published in:
- Journal of Clinical Pharmacology, 2017, v. 57, n. 5, p. 678, doi. 10.1002/jcph.907
- Publication type:
- Article
5
The Journal of Clinical Pharmacology, Clinical Pharmacology in Drug Development, and the Impact Factor.
- Published in:
- Journal of Clinical Pharmacology, 2017, v. 57, n. 5, p. 545, doi. 10.1002/jcph.909
- By:
- Publication type:
- Article
6
Population Pharmacokinetics and Exposure-Response Relationship of Carfilzomib in Patients With Multiple Myeloma.
- Published in:
- Journal of Clinical Pharmacology, 2017, v. 57, n. 5, p. 663, doi. 10.1002/jcph.850
- By:
- Publication type:
- Article
7
Issue Information.
- Published in:
- Journal of Clinical Pharmacology, 2017, v. 57, n. 5, p. 539, doi. 10.1002/jcph.927
- Publication type:
- Article
8
Impact of Target-Mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9).
- Published in:
- Journal of Clinical Pharmacology, 2017, v. 57, n. 5, p. 616, doi. 10.1002/jcph.840
- By:
- Publication type:
- Article
9
Cefiderocol, a Siderophore Cephalosporin for Gram-Negative Bacterial Infections: Pharmacokinetics and Safety in Subjects With Renal Impairment.
- Published in:
- Journal of Clinical Pharmacology, 2017, v. 57, n. 5, p. 584, doi. 10.1002/jcph.841
- By:
- Publication type:
- Article
10
A Novel NF-κB Inhibitor, Edasalonexent (CAT-1004), in Development as a Disease-Modifying Treatment for Patients With Duchenne Muscular Dystrophy: Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics in Adult Subjects.
- Published in:
- Journal of Clinical Pharmacology, 2017, v. 57, n. 5, p. 627, doi. 10.1002/jcph.842
- By:
- Publication type:
- Article
11
Markov Mixed Effects Modeling Using Electronic Adherence Monitoring Records Identifies Influential Covariates to HIV Preexposure Prophylaxis.
- Published in:
- Journal of Clinical Pharmacology, 2017, v. 57, n. 5, p. 606, doi. 10.1002/jcph.843
- By:
- Publication type:
- Article
12
Model-Based Dose Selection for Intravaginal Ring Formulations Releasing Anastrozole and Levonorgestrel Intended for the Treatment of Endometriosis Symptoms.
- Published in:
- Journal of Clinical Pharmacology, 2017, v. 57, n. 5, p. 640, doi. 10.1002/jcph.846
- By:
- Publication type:
- Article
13
Pharmacokinetics of a Single Oral Dose of the MEK1/2 Inhibitor Selumetinib in Subjects With End-Stage Renal Disease or Varying Degrees of Hepatic Impairment Compared With Healthy Subjects.
- Published in:
- Journal of Clinical Pharmacology, 2017, v. 57, n. 5, p. 592, doi. 10.1002/jcph.848
- By:
- Publication type:
- Article
14
Population Pharmacokinetics of Ceritinib in Adult Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase.
- Published in:
- Journal of Clinical Pharmacology, 2017, v. 57, n. 5, p. 652, doi. 10.1002/jcph.849
- By:
- Publication type:
- Article